Recent Finacing
Recent Raise
Dren Bio designs bispecific antibody therapeutics using a Targeted Myeloid Engager and Phagocytosis Platform to induce antigen-dependent myeloid phagocytosis, advancing DR-01 and DR-0201 across oncology and autoimmune programs.
